Lantheus HoldingsLNTH +0.12%82 FCF Yield % is 5.23 as of Jul. 02, 2026, which is 9% below its 10-year median of 5.75. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.85 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Lantheus Holdings ranks better than 74.45% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lantheus Holdings FCF Yield % Related Terms
Lantheus Holdings FCF Yield % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a FCF Yield % of 5.23 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lantheus Holdings and its competitors. This is near median its historical median of 5.75. Over the past decade, Lantheus Holdings' FCF Yield % has ranged from 0.24 to 23.13. According to the industry distribution chart, Lantheus Holdings ranks #257 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 25.5%.
Is Lantheus Holdings' FCF Yield % too high?
Lantheus Holdings' current FCF Yield % of 5.23 is near median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 23.13. The Drug Manufacturers industry median FCF Yield % is 0.66. Lantheus Holdings' value of 5.23 is 698.5% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #257 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' FCF Yield % compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #257 out of 1006 companies for FCF Yield %. This puts Lantheus Holdings in the upper half of its industry. The industry median FCF Yield % is 0.66. Lantheus Holdings' value of 5.23 is 698.5% above this benchmark. Historically, Lantheus Holdings' own FCF Yield % has ranged from 0.24 to 23.13 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 0.66, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.66, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current FCF Yield % of 5.23 is 698.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current FCF Yield % is 5.23, which is near median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $109.07 — trading 20% above its estimated fair value. The current FCF Yield % is 5.23, which is near median its 10-year median of 5.75 and 698.5% above the Drug Manufacturers industry median of 0.66. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current FCF Yield % is 5.23 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $109.07 is trading 20% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
FCF Yield %: 5.23 (near median its 10-year median of 5.75)
GF Value™: $90.85 vs. price of $109.07 (20% above fair value)
Industry Position: 698.5% above the Drug Manufacturers median (#257 of 1006)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
